



## Press release

### Number of shares and votes in BioArctic AB (publ) as of May 29, 2026

**Stockholm, May 29, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 5,000 stock options of series 2019/2028**

As of May 29, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,724,485 shares, of which 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes in the company amounts to 218,324,449.

---

*This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on May 29, 2026, at 6:30pm CET.*

**For further information, please contact:**

Oskar Bosson, VP Communications and Investor Relations

E-mail: [oskar.bosson@bioarctic.com](mailto:oskar.bosson@bioarctic.com)

Telephone: +46 704 107 180

Jenny Ljunggren, External Communications and Investor Relations Manager

E-mail: [jenny.ljunggren@bioarctic.com](mailto:jenny.ljunggren@bioarctic.com)

Telephone: +46 76 013 86 08

**About BioArctic AB**

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit [www.bioarctic.com](http://www.bioarctic.com).